A new trading day began on Friday, with Editas Medicine Inc (NASDAQ: EDIT) stock price down -23.81% from the previous day of trading, before settling in for the closing price of $1.89. EDIT’s price has ranged from $1.86 to $11.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 101.57% over the last five years. Meanwhile, its annual earnings per share averaged -30.62%. With a float of $81.78 million, this company’s outstanding shares have now reached $82.54 million.
The firm has a total of 265 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.46%, operating margin of -370.03%, and the pretax margin is -340.96%.
Editas Medicine Inc (EDIT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 67.87%. The most recent insider transaction that took place on Dec 03 ’24, was worth 3,361. In this transaction CEO of this company sold 1,618 shares at a rate of $2.08, taking the stock ownership to the 312,106 shares. Before that another transaction happened on Dec 03 ’24, when Company’s EVP, CHIEF MEDICAL OFFICER sold 541 for $2.08, making the entire transaction worth $1,124. This insider now owns 133,354 shares in total.
Editas Medicine Inc (EDIT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Here are Editas Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.53 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Analysing the last 5-days average volume posted by the [Editas Medicine Inc, EDIT], we can find that recorded value of 4.2 million was better than the volume posted last year of 2.02 million. As of the previous 9 days, the stock’s Stochastic %D was 10.04%. Additionally, its Average True Range was 0.21.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 0.68%, which indicates a significant decrease from 2.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 129.75% in the past 14 days, which was higher than the 81.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.7802, while its 200-day Moving Average is $4.7499. Now, the first resistance to watch is $1.6700. This is followed by the second major resistance level at $1.9000. The third major resistance level sits at $2.0300. If the price goes on to break the first support level at $1.3100, it is likely to go to the next support level at $1.1800. Should the price break the second support level, the third support level stands at $0.9500.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
With a market capitalization of 90.57 million, the company has a total of 82,548K Shares Outstanding. Currently, annual sales are 78,120 K while annual income is -153,220 K. The company’s previous quarter sales were 60 K while its latest quarter income was -62,140 K.
